Drug intelligence / Profile preview

methylprednisolone + paracetamol + dexchlorpheniramine

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

This is a fixed-dose combination drug containing three active ingredients: - **Methylprednisolone** is a synthetic corticosteroid that suppresses inflammation and immune responses by modulating gene expression, reducing the production of inflammatory mediators, and inhibiting leukocyte infiltration. It is used to treat conditions such as severe allergies, asthma, autoimmune disorders, and certain cancers[1][5]. - **Paracetamol** (also known as acetaminophen) is an analgesic and antipyretic agent that reduces fever and relieves mild to moderate pain. Its mechanism involves inhibition of prostaglandin synthesis in the central nervous system. - **Dexchlorpheniramine** is a first-generation antihistamine that acts as an antagonist at histamine H1 receptors, providing relief from allergic symptoms like runny nose, sneezing, itching, and watery eyes[2][7]. The combination may be used for symptomatic relief in conditions involving inflammation or allergy with associated pain or fever.

02

Targets

GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on methylprednisolone + paracetamol + dexchlorpheniramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylprednisolone + paracetamol + dexchlorpheniramine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call